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High steroid doses are often necessary in congenital adrenal hyperplasia (CAH) to suppress androgens and may increase blood
pressure (BP). We evaluated 24-hour BP profile (ambBP), BP during exercise (excBP), and echocardiography in 20 young CAH
patients. Systolic and diastolic BP during ambBP and excBP was normal in all patients. None presented myocardial hypertrophy.
Nocturnal diastolic BP was aﬀected by testosterone (P: .016, 95% CI: 0.002 to 0.021, β = 0.01). Left ventricular mass (LVM ) was
aﬀected by height SDS (P: .007, 95% CI: 2.67 to 14.17, β = 8.42), age (P: < .0001, 95% CI: 2.12 to 5.82, β = 3.97), and testosterone
(P: .008, 95% CI: 0.01 to 0.09, β = 0.053). Left ventricular mass index (LVMI) correlated with BMI SDS (P: .044, 95% CI: 0.09 to
6.17, β = 3.13) and testosterone (P: .031, 95% CI: 0.002 to 0.035, β = 0.018). Hydrocortisone dose did not influence ambBP, excBP,
or myocardial hypertrophy.
Copyright © 2009 Graziamaria Ubertini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
The 21 hydroxylase deficiency is the most common enzyme
defect causing congenital adrenal hyperplasia (CAH). It is
distinguished by the severity of the enzyme defect, in classical
and non classical form. Approximately 70% individuals with
classical CAH are aﬀected by the more severe salt-wasting
(SW) form, characterized by androgen hyper secretion
and impaired synthesis of both glucocorticoids (GCs) and
mineralcorticoids (MCs). About 20%–30% patients are
aﬀected by the milder simple virilizing (SV) form, where
the excessive androgen production results in virilization,
but the synthesis of MCs is suﬃcient to avoid salt wasting
crises. The non classical form is characterized by later and
milder signs of androgen excess as precocious pubarche
[1].
The treatment of CAH is based on GCs therapy, in
order to suppress the androgen production trough the
inhibition of CRH and consequently ACTH. The therapy
must be balanced to avoid poor linear growth, obesity and
hypertension.
Several factors may interfere with the physiological con-
trol of BP in patients aﬀected by CAH due to 21 hydroxilase
deficiency: (a) over treatment with GCs and MCs; (b)
elevated GCs levels that aﬀect the MCs receptor (MR); (c)
impaired adrenomedullary function, with a negative impact
on sympathetic control of BP; (d) obesity itself [2–5].
An alteration in endothelial function has been demon-
strated in GCs excess. Dexamethasone induces overproduc-
tion of reactive oxygen species causing dysregulation of the
endothelial function. A reduction of nitric oxide levels, with a
reduction of arteriolar vasodilatation has been demonstrated
in GCs-induced hypertension [6].
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MR binds progesterone, deoxycorticosterone (DOC),
corticosterone, cortisol and aldosterone with a similar high
aﬃnity, but only DOC and aldosterone are full agonists of the
MR. Corticosterone and cortisol have lower transcriptional
activity on the MR, and elevated levels of these steroids
are necessary to aﬀect the MR. Hypertension in Cushing
syndrome is mainly due to the eﬀects of the elevated GCs
levels on MR [2, 7]. High serum leptin and insulin levels and
low plasma epinephrine levels have been demonstrated in
CAH. They are probably due to the chronic adrenomedullary
hypofunction, associated with the impaired synthesis of
cortisol that normally induces the formation of adrenal
medulla [8]. These alterations could contribute to determine
insulin resistance, metabolic syndrome and cardiovascular
disease.
Little is known about early BP and cardiovascular
changes in CAH patients and their correlation with androgen
levels and chronic steroid therapy.
2. Aim of the Study
Aim of our study was to search for early cardiovascular
changes in young CAH patients, by the analysis of ambula-
tory 24-hour BP profile (ambBP), BP levels during physical
exercise (excBP), and echocardiography. We investigated if
androgen levels and GCs therapy could aﬀect BP and heart
function parameters.
3. Patients
We analysed 20 patients (14 females and 6 males), aﬀected
by classical CAH due to 21 hydroxylase deficiency (15 SW, 5
SV). All participants were Caucasian of Italian ancestry. The
diagnosis was confirmed by molecular analysis in all patients.
Seven females and 2 males were pubertal. They all received
hydrocortisone (HC) therapy, twice or thrice daily at a mean
dosage of 14.16 ± 5.46 mg/m2/day. The 15 patients with
SW CAH assumed also fludrocortisone at a mean dose of
0.06± 0.02 mg/day. The institutional review board approved
the study, informed assent and consent were obtained from
the subjects and their parents or guardians. Anthropometric,
clinical and hormonal characteristics of our patients are
summarized in Table 1.
4. Hormone Assay
Commercial kits were used for the estimation of 17-OH-
progesterone (RIA, ICN-Pharmaceutical Inc.) and plasma
renin (RIA, Sanofi-Pasteur). Mean intra- and interassay
coeﬃcients of variation where 8.8% and 12% for 17-OH-
progesterone, 7, 9% and 10% for plasma renin. Testosterone
levels were measured by chemiluminescence immunoassay
(Centaur-Bayer), intra and interassay coeﬃcients of vari-
ation were 3.8% and 5%, respectively. ACTH concentra-
tions were determined by immonoradiometric assay (ACTH
IRMA, Nichols Institute Diagnostics), with a sensitivity of
1 pg/mL. Intra- and interassay variability 3.2% and 6.8%,
respectively.
Table 1: Anthropometric clinical and hormonal characteristics of
the study group.
Mean (±SD) Median (range)
Age (years) 13.38 (±4.11) 13.62 (5.1–17.49)
Height SDS −0.27 (±1.23) −0.73 (−1.63 + 2.24)
BMI SDS 1.05 (±0.82) 1.02 (−0.14 + 2.46)
17-OH-progesterone 16.71 (±16.78) 11 (0.2–54)
(ng/mL)
ACTH (pg/mL) 88. 09 (±50.98) 64.0 (1.6–310)
Plasma renin (pg/mL) 53.43 (±43.52) 22.5 (1.3–450)
Testosterone (ng/dL) 85.71 (±65.19) 73.06 (10–225.3)
Hydrocortisone dose 14.16 (±5.46) 13.58 (10.06–21.3)
(mg/m2/day)
5. Definition of Hypertension in Children
The diagnosis of hypertension in paediatric age has to take
into consideration the criteria to define normal BP levels
in children. The first age-related norms for BP in children
were developed in 1977 by the Task Force on Blood pressure
Control in Children [9].
The standards were revised in 1987 by a second task force
that evaluated data from 70 000 White, African American
and Mexican-American children [9]. In this revision, tables
of normal BP according to age and gender were published.
High BP was defined as systolic and/or diastolic BP between
the 90th and 95th centile for age and gender. Hypertension
was defined as systolic and/or diastolic BP greater than the
95th centile for age and gender. In the last revision, published
in 1996, height was added to age and gender as a category in
the standard BP tables [9].
Finally, to analyse BP in childhood, we have now to take
in account of gender, age and height. Obesity is considered
as an independent additional risk factor for hypertension in
children, but weight or BMI are not included as categories in
the tables of normal BP [10].
6. Methods
All CAH patients underwent ambBP profile during their
normal daily activities, for the analysis of mean diurnal and
nocturnal systolic and diastolic BP (SBP and DBP).
They also underwent endurance treadmill exercise by
Bruce test (excBP), for the evaluation of BP levels at maximal
heart rate. Bruce test consists in a progressive multistage
treadmill test to volitional exhaustion [11]. Seven 3-minutes
stages were used, in which the speed and inclination
were increased in a stepwise fashion as follows: stage 1
(2.7 km/h and 10% inclination); stage 2 (4.0 km/h and 12%
inclination); stage 3 (5.4 km/h and 14% inclination); stage
4 (6.7 km/h and 16% inclination); stage 5 (8.0 km/h and
18% inclination); stage 6 (8.8 km/h and 20% inclination);
stage 7 (10.6 km/h and 22% inclination). Heart rate was
continuously measured throughout the test, using a cardio
tester (Polar, Electro Oy, Finland). The treadmill was stopped
when each participant refused to continue the exercise
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test, despite verbal encouragement from the research staﬀ.
Maximal heart rate (beats/min), SBP and DBP were recorded
at the end of the test. All tests were closely physician-
monitored and performed in the morning, after an overnight
fast. The morning doses of HC and fluodrocortisone were
administered at the end of the test. All patients familiarized
with treadmill at least one week before the test, in order
to avoid psychological stress. BP values were compared
to Task Force references for after endurance exercise BP
[10].
All participants were studied by echocardiography using
a Philips iE33 Echocardiography System, in order to eval-
uate heart function and myocardial hypertrophy. Two-
D guided M-mode measurements of the left ventricular
internal dimension were made during diastole, according to
established methods by the American Society of Echocardio-
graphy [12]. Left ventricular mass (LVM) increases during
growth and thus normal must be defined in the context of
body size. LVM has been adjusted for height, body surface
area and BMI raised to various powers. Height2.7(in meters)
has been validated as an indicator of lean body mass and
has been recommended for indexing LVM. Use of height2.7
to index LVM also minimizes the eﬀect of age, gender and
race [13]. We determined the following measurements on M-
mode tracing:
(a) interventricular septum thickness (IVS), in millime-
ters;
(b) left ventricular posterior wall thickness (LVPW), in
millimeters;
(c) left ventricular mass (LVM): calculated from mea-
surement of the left ventricle (LV) by using the trun-
cated ellipsoid methods by two-dimensional (2D)
echocardiography recommended from the American
Society of Echocardiography [12], in grams;
(d) left ventricular mass index (LVMI): representing
LVM corrected for height (= LVM/meters2.7); left
ventricular hypertrophy was defined as LVMI > 95◦
centile for paediatric age [14], that is > 38.6 g/m2.7.
7. Statistical Analyses
Statistical analyses were conducted using STATA Statistical
Software Package, Release 10.1 (STATA, College station, TX,
USA). Clinical and hormonal data are presented both as
means ± standard deviation (SD) and medians (range),
although we confirmed by Skewness/Kurtosis tests that all
the analyzed variables were normally distributed. T-test was
used to analyze the gender related diﬀerences. Multivariable
linear regression models were fitted in order to evaluate
the independent eﬀect of each covariate (age, height SDS,
BMI SDS, testosterone, 17-OH-progesterone, ACTH, HC
dose) on ambBP profile, excBP and myocardial hypertrophy
parameters (IVS, LVPW, LVM, LVMI). A P value < .05 was
considered significant.
Table 2: Results of the 24-hours ambBP profile, excBP and
echocardiography in CAH patients.
Mean ± SD Median (range)
Mean diurnal SBP
107.29± 7.14 109 (95–122)
(mmHg)
Mean diurnal DBP
62.57± 5.08 61 (56–72)
(mmHg)
Mean nocturnal SBP
97.43± 7.43 99.0 (85–116)
(mmHg)
Mean nocturnal DBP
53.33± 4.44 52 (45–64)
(mmHg)
Duration of exercise
10.02± 3.62 10 (75–14)
(minutes)
Maximal heart rate
187.19± 7.05 188 (170–200)
(beats/min)
SBP at maximal heart rate
132.38± 18.14 130 (100–170)
(mmHg)
DBP at maximal heart rate
76.38± 10.89 80 (60–100)
(mmHg)
LVM (g) 76.22± 24.60 75.9 (35–119)
LVMI (g/m2.7) 24.80± 5.04 23.54 (11.25–34.27)
LVPW (mm) 5.95± 0.91 5.8 (3.7–7.4)
IVS (mm) 6.22± 1.16 6.0 (4.9–8.9)
8. Results
We calculated the mean diurnal and nocturnal values of SBP
and DBP from the 24-hour ambBP profile and compared
them with the BP percentiles, according to the Task Force on
Blood Pressure Control in Children [9].
No patient presented mean diurnal SBP or DBP sugges-
tive of hypertension (defined as BP levels superior to 95th
percentile). No patient presented mean SBP or DBP in the
high normal BP range (defined as BP between 90th and 95th
percentile). Mean diurnal SBP and DBP were significantly
higher than nocturnal BP levels (diurnal SBP: 107.29 mmHg
±7.14, nocturnal SBP: 97.43 mmHg ±7.43 −P: < .0001;
diurnal DBP: 62.57 mmHg ±5.08, nocturnal DBP: 53.33
mmHg ±4.44 −P: < .0001). At maximal heart rate during
Bruce test, SBP was in the normal range in all patients, while
7 patients (33,3%—6F, 1M) presented high DBP (between
the 90th and the 95th centile). The results of ambBP profile
and excBP are showed in Table 2.
We did not find any gender related diﬀerences in 24-
hour ambBP profile, excBP and myocardial hypertrophy
parameters.
Multivariable linear regression showed that mean diurnal
SBP, from the 24-hour ambBP profile, was negatively related
to 17-OH-progesterone levels (P: .026, 95% CI: −0.34 to
−0.02, β = −0.18), while mean diurnal DBP was positively
related to age (P: .003, 95% CI: 0.29 to 1.28, β = 0.79) and to
height SDS (P: .029, 95% CI: 0.22 to 3.52, β = 1.87). Mean
nocturnal DBP was aﬀected by testosterone levels (P: .016,
95% CI: 0.002 to 0.021, β = 0.01). SBP at maximal heart rate
during exercise was influenced by age (P < .0001, 95% CI:
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Figure 1: Correlation between BMI SDS and LVMI (P: 0.044).
1.79 to 4.67, β = 3.23), whereas DBP showed a correlation
both with age (P:< .0001, 95% CI: 1.30 to 3.03, β = 2.20) and
with BMI SDS (P: .033, 95% CI: 0.40 to 8.76, β = 4.58). No
CAH patient presented left ventricular hypertrophy, defined
by the published paediatric criteria (LVMI > 38.6 g/m2.7).
Multivariable linear regression showed that LVM was aﬀected
by height SDS (P: .007, 95% CI: 2.67 to 14.17, β = 8.42),
by age (P:< .0001, 95% CI: 2.12 to 5.82, β = 3.87) and by
testosterone levels (P: .008, 95% CI: 0.01 to 0.09, β = 0.053).
LVMI was positively related to BMI SDS (P: .044, 95% CI:
0.09 to 6.17, β = 3.13—Figure 1), and to testosterone levels
(P: .031, 95% CI: 0.002 to 0.035, β = 0.018). LVPW was
aﬀected only by age (P: .008, 95% CI: 0.03 to 0.19, β = 0.11).
HC dose did not influence 24-hour ambBP profile, excBP,
and echocardiographic parameters.
9. Discussion
Our data suggest that ambBP profile and excBP are substan-
tially normal in young CAH patients with good hormonal
balance. Our CAH patients were not over treated, despite a
fairly good hormonal balance. Mean HC dose corresponded
nearly to a replacement dose and it could not be considered
as supra physiologic. In this conditions nocturnal systolic
and diastolic BP dips were maintained; neither ambBP
profile nor excBP were aﬀected by HC dose. A few recent
studies, investigating BP profile in CAH patients, have
reported conflicting results.
Roche et al. [15] in 2003 studied with ambBP monitoring
37 children, aged between 6.1 and 18.2 years, aﬀected by
SW CAH. Mean daytime SBP was higher than the reference
population, 58% of patients had systolic hypertension. Mean
daytime DBP was also elevated and 24% patients had
diastolic hypertension. In 84% of patients the physiological
nocturnal dip of SBP was absent. They demonstrated that
higher BP levels in CAH patients are positively correlated
with higher BMI. De Silva et al. [16] in 2004 showed a normal
24-hour ambBP profile in 11 CAH patients. All patients
were on GCs replacement therapy at supra-physiologic doses.
Mean SBP and DBP during awake and sleep period, systolic
and diastolic BP loads and dips were calculated from the
ambBP and compared to Task Force References for BP. None
of the patients showed BP loads above the 95th percentile.
As previously described in healthy subjects, in our CAH
patients, BP seems to be primarily related to age, BMI and
height. In 2006 Vo¨lkl et al. [17] analysed the eﬀect of BMI,
fat mass (skin fold thickness), GCs and MCs treatment
and skeletal maturation on BP. They studied 55 Caucasian
classical CAH subjects (45 SW and 10 SV; 32 females and
23 males), aged between 5 and 19 years. All of them were
treated with GCs, 53 received additional MCs. A BMI higher
than +2 SDS was found in 27.3% of patients, versus 2.27%
of the general population. Mean diurnal and nocturnal SBP
levels were significantly elevated. BMI and serum leptin were
positively correlated with skin fold thickness. No correlation
between GCs dose and BP was found. The authors concluded
that obese CAH children and adolescents presented an higher
risk to develop systolic hypertension.
The same group [18] analysed BMI SDS in children
and adolescents aﬀected by CAH. A BMI greater than +2
SDS was found in 16.8% of CAH patients. The BMI SDS
did not diﬀer between children treated by diﬀerent GCs
(HC, prednisone or dexamethasone), but it was significantly
correlated to the equivalent HC dose. Knorr and Hinrichsen-
de-Lienau [19] found a significant relationship between over
treatment with HC during the first 2 years of age and later
development of obesity among young adults. Our CAH
patients showed a mean BMI SDS in the normal range, with
only one obese subject (BMI: 32 kg/m2). Nevertheless, DBP
at maximal heart rate during exercise and LVMI showed a
significant positive correlation with BMI SDS, confirming
that these parameters can be considered as early warnings for
hypertension and cardiac overload in obese patients.
In our study group, mean diurnal SBP was negatively
correlated to 17-OH-progesterone levels, suggesting that a
poor hormonal balance, with mild GCs and MCs deficiency
and high levels of androgen precursors, could determine
blood hypotension. Conversely, mean nocturnal DBP was
positively correlated to testosterone levels, suggesting that
higher nocturnal DBP could represent and early eﬀect of
androgen excess. We did not find any gender related diﬀer-
ences in 24-hour ambBP, excBP, and myocardial hypertrophy
parameters. The lack of gender dimorphism in cardiovascu-
lar parameters could be related to the lower diﬀerences in
androgen levels between males and females in young CAH
patients.
Myocardial hypertrophy with increased left ventricu-
lar wall thickness and greater LVMI had been repeatedly
described in subjects with high GCs levels due to Cushing’s
syndrome [20, 21].
Androgenic anabolic steroids, used for improving phys-
ical performance, have been considered responsible for
myocardial hypertrophy, acute myocardial infarction and
sudden death in humans [22] and animal models [23].
On the contrary, left ventricular hypertrophy and its
correlation with androgen levels and GCs therapy had never
been investigated in CAH patients. We did not find any
evidence of myocardial hypertrophy (LVMI > 38.6 g/m2.7)
in our study group. A normal mean LVMI confirms that the
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mean HC dose usually used is not really supra physiologic,
in spite of a good hormonal balance. On the other hand,
testosterone levels positively aﬀect myocardial hypertrophy
parameters (LVM and LVMI), suggesting that androgens
excess could have a detrimental eﬀect on myocardial func-
tion. Due to the small sample size, these data should not be
considered as conclusive. Particularly in the 2 pubertal males,
we cannot exclude a normal influence of increasing gonadal
androgens on LVM and LVMI.
10. Conclusions
The present study suggests that BP levels are substantially
normal in young CAH patients. BP levels are not influenced
by HC dose, at least when the doses are not straightforwardly
supra physiologic. As described in healthy subjects, age,
height and BMI are the main determinants of BP; high DBP
during exercise and LVMI indicate an early warning sign
for hypertension, positively related to BMI. High androgen
levels in CAH patients seem to be an additional long term
risk factor for hypertension and myocardial hypertrophy.
The small sample size and the wide age span are significant
limitations of our study and do not allow a generalization of
the results.
If confirmed in larger trials, the increasing of mean
nocturnal DBP, LVM and LVMI could represent early
markers of cardiovascular damage due to androgen excess.
The systematic monitoring of BP, BMI, and eventually
echocardiography is important to recognize early changes of
these parameters and to prevent cardiovascular morbidity in
adult CAH patients.
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